Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2012

Labor L+S to Offer Symbiosis’ Analytical Tests

  • Labor L+S and Symbiosis entered into an exclusive business alliance for analytical testing. From May 1, Labor L+S will be able to offer to its customers services and solutions from Symbiosis.

    The arrangement expands Labor L+S’ portfolio, and its clients will be able to order services through a single point of contact for all stages of the drug development life cycle. “Our goal at Labor L+S is to continuously extend the range of required services that meet the regulatory and scientific needs of our clients in the pharmaceutical and biotech industry,” remarks Lothar Bomblies, member of the management board of Labor L+S.

    “This business alliance with Symbiosis enhances our ability to exceed client expectations by offering cost-effective, innovative analytical services that accelerate the development, production, and safety assessment of their pharmaceutical or biopharmaceutical product.”

    Symbiosis is the newly created business division of Biopharm that offers a spectrum of analytical services for biologics and pharmaceuticals under GMP/GLP. Labor L+S is an independent, private contract laboratory offering quality control investigations for the pharmaceutical and hygiene industries. Since 1987, the company has been providing services in the fields of microbiology, assays, analytical chemistry, and molecular biology. Labor L+S operates in conformity with GMP, has a manufacturing license, and is accredited according to ISO 17025.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »